Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence

Husein‐ElAhmed, Husein; Steinhoff, Martin

doi:10.1080/09546634.2021.1914315

Cited by 11 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some reports have documented a positive correlation between IL-12p40 and AD severity (121). Consistently, blockage of IL-12p40 resulted in complete remission of AD in one-third of patients, partial remission in another third, and lack of response in the remaining third (243). Considering that IL-12p40 is shared between IL-12 and IL-23, the observed promising outcome cannot be fully attributed to IL-12; it may instead reinforce the importance of IL-23/IL-17 axis.…”

Section: Interleukin-12mentioning

confidence: 72%

The role of cytokines in atopic dermatitis: a breakthrough in immunopathogenesis and treatment

Alsabbagh¹,

Ismaeel²

2022

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

View full text Add to dashboard Cite

Atopic dermatitis is a multifactorial inflammatory skin disease with a complex immunopathogenesis that is characterized by an underlying imbalance of T-cell subsets. Although cytokines of type 2 immunity consistently predominate in the acute phase of atopic dermatitis, there is strong evidence supporting the contribution of cytokines of type 1 immunity, type 3 immunity, and other cytokines in the development and progression of the disease. This review explores the cytokine network in atopic dermatitis, and it highlights areas and causes of controversy in the immunopathogenesis of the disease. In addition, it presents the current therapeutic targets currently being investigated, including monoclonal antibodies and small molecules that inhibit cytokines and downstream signaling molecules in atopic dermatitis. We conclude that atopic dermatitis has a complex and controversial cytokine profile. Understanding the role of cytokines in the immunopathogenesis of the disease is essential for identifying personalized targets for better management and disease control.

show abstract

Section: Interleukin-12mentioning

confidence: 72%

The role of cytokines in atopic dermatitis: a breakthrough in immunopathogenesis and treatment

Alsabbagh¹,

Ismaeel²

2022

Acta Dermatovenerologica Alpina Pannonica Et Adriatica

View full text Add to dashboard Cite

show abstract

“…However, it is now recognized that these entities can co-exist 11 In our case, it is interesting to note that tildrakizumab managed to control both the psoriatic and eczematous components. Moreover, there are anecdotical reports of IL12/23 inhibitors in atopic dermatitis with good outcomes, highlighting that the impact of anti-IL-12/IL-23p40 therapy in eczematous diseases is still unclarified 12 .…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, there are anecdotical reports of IL12/23 inhibitors in atopic dermatitis with good outcomes, highlighting that the impact of anti-IL-12/IL-23p40 therapy in eczematous diseases is still unclarified. 12 …”

Section: Discussionmentioning

confidence: 99%

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psoriasis, involving primarily upper limbs, elbow, abdomen and knees (PASI 18 – DLQI 22). His medical history was relevant for epilepsy controlled pharmacologically. In addition, an eczematous and edematous appearance of the tibial area was detected; the histologic findings did not contradict the diagnostic hypothesis of subacute spongiotic dermatitis. The patient was treated with Tildrakizumab. After 12 weeks the clinical lesions improved significantly, and the eczematous component disappeared in the tibial area bilaterally. The clinical improvement was maintained even after one year of therapy. Tildrakizumab showed excellent results in the control of psoriasis, with an excellent safety profile. The promising results of clinical trials have been confirmed in a real-life setting. There are no reports about its safety in epileptic patients. In our case, neurological adverse events did not verify and tildrakizumab managed to control both the psoriatic and eczematous components.

show abstract

“…Case reports and case series suggest that ustekinumab may be effective in the treatment of pruritus in the course of atopic dermatitis [ 67 , 68 , 69 , 70 ]. However, no satisfactory response was confirmed in phase II placebo-controlled clinical trials [ 71 , 72 ] or more extensive real-life observations [ 73 ]. No further clinical studies on this matter are currently being conducted [ 55 ].…”

Section: Il-12/23-targeted Therapiesmentioning

confidence: 99%

The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis

Hołdrowicz,

Woźniacka

2024

JCM

View full text Add to dashboard Cite

Atopic dermatitis is a heterogenous inflammatory disease with high variety in terms of clinical symptoms and etiopathogenesis, occurring both in pediatric and adult populations. The clinical manifestation of atopic dermatitis varies depending on the age of patients, but all age groups share certain common features, such as a chronic and recurrent course of disease, pruritus, and a co-occurrence of atopic diseases in personal or family medical history. Treating pruritus is a high priority due to its incidence rate in atopic dermatitis and substantial impact on quality of life. In recent years, treatments with biological drugs have increased the range of therapeutic possibilities in atopic dermatitis. The aim of the study is to present the safety profile, efficacy, and effectiveness of various biological treatment methods for the therapy of pruritus in the course of atopic dermatitis.

show abstract

Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence

Cited by 11 publications

References 44 publications

The role of cytokines in atopic dermatitis: a breakthrough in immunopathogenesis and treatment

The role of cytokines in atopic dermatitis: a breakthrough in immunopathogenesis and treatment

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis

Contact Info

Product

Resources

About